By Justin Gambill, Manager, Program Management
In the Rare Disease space, a product NDC may change for any of several reasons. Whether it’s a new product formulation on the market or a new company inheriting a previously established product, it’s imperative to think through the potential impact that a product NDC change may have on your established patient population. Here are a few things to consider that could reduce potential therapy gaps for patients when an NDC change is imminent.
Here are a few ways that utilizing a HUB with experienced clinical staff may be able to assist in helping to overcome/address authorization denials.